A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-10-12
DOI
10.1038/s41467-022-33267-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development and validation of a targeted sequencing panel for application to treatment-refractory solid tumor.
- (2021) Woo Sun Kwon et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
- (2021) J.Y. Wang et al. ANNALS OF ONCOLOGY
- Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
- (2021) Joseph J. Zhao et al. JOURNAL OF CLINICAL ONCOLOGY
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
- (2021) Yelena Y. Janjigian et al. NATURE
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
- (2020) Kwoneel Kim et al. Nature Communications
- KRGDB: the large-scale variant database of 1722 Koreans based on whole genome sequencing
- (2020) Kwang Su Jung et al. Database-The Journal of Biological Databases and Curation
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
- (2020) Regina Padmanabhan et al. Cancers
- Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers
- (2020) Dongfeng Niu et al. PATHOLOGY & ONCOLOGY RESEARCH
- LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
- (2020) N. Boku et al. ANNALS OF ONCOLOGY
- LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
- (2020) M. Moehler et al. ANNALS OF ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
- (2020) Hyun Cheol Chung et al. Future Oncology
- Alterations in DNA damage repair genes in primary liver cancer
- (2019) Jianzhen Lin et al. CLINICAL CANCER RESEARCH
- MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
- (2019) Thijs S Stutvoet et al. JOURNAL OF PATHOLOGY
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
- (2019) Jacqulyne P. Robichaux et al. CANCER CELL
- Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
- (2019) Diego Chowell et al. NATURE MEDICINE
- TAPES: A tool for assessment and prioritisation in exome studies
- (2019) Alexandre Xavier et al. PLoS Computational Biology
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
- (2018) Bharat K.R. Chaganty et al. CANCER LETTERS
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- (2018) Francisco Sanchez-Vega et al. CELL
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Maftools: efficient and comprehensive analysis of somatic variants in cancer
- (2018) Anand Mayakonda et al. GENOME RESEARCH
- Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome
- (2018) Scott D. Brown et al. OncoImmunology
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
- (2017) Frédéric Bigot et al. EUROPEAN JOURNAL OF CANCER
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
- (2017) Angela N. Bartley et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Korean Variant Archive (KOVA): a reference database of genetic variations in the Korean population
- (2017) Sangmoon Lee et al. Scientific Reports
- Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
- (2017) Aura Muntasell et al. Frontiers in Immunology
- ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization
- (2016) Guangchuang Yu et al. Molecular BioSystems
- Analysis of protein-coding genetic variation in 60,706 humans
- (2016) Monkol Lek et al. NATURE
- Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy
- (2016) Hyo Song Kim et al. Oncotarget
- An integrative approach to predicting the functional effects of non-coding and coding sequence variation
- (2015) Hashem A. Shihab et al. BIOINFORMATICS
- Clonality inference in multiple tumor samples using phylogeny
- (2015) Salem Malikic et al. BIOINFORMATICS
- A global reference for human genetic variation
- (2015) Richard A. Gibbs et al. NATURE
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- PyClone: statistical inference of clonal population structure in cancer
- (2014) Andrew Roth et al. NATURE METHODS
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer
- (2011) Young Wha Koh et al. MODERN PATHOLOGY
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Amino acid interaction preferences in proteins
- (2010) Anupam Nath Jha et al. PROTEIN SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now